Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TaPPiNG-EPI

Financiado

Cerrado

Targeting Purinergic Pathway in drug resistant epilepsy using human Neurons and...

Targeting Purinergic Pathway in drug resistant epilepsy using human Neurons and Glia. Epilepsy is a neurological disorder characterized by recurrent seizures affecting 65 million people worldwide of which 6 million live in Europe alone with around 30% of patients not responding to currently available treatment. The... ver más

31/03/2021

ROYAL COLLEGE OF S...

197K€

Presupuesto del proyecto: 197K€

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-03-31

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ROYAL COLLEGE OF SURGEONS IN...

196.59K€ | Lider

Proyectos interesantes

EpiPur

Medical Technol...

Applied Physics

176K€ Cerrado

EpiPrevent

Medical Technol...

Applied Physics

216K€ Cerrado

PurinesDX

Medical Technol...

Applied Physics

3M€ Cerrado

EpiPurines

Medical Technol...

Data Science

258K€ Cerrado

RTI2018-098768-B-I00

Medical Technol...

Applied Physics

230K€ Cerrado

PanThera

Medical Technol...

Pharmaceutical...

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 24 meses Fecha Inicio: 2019-03-19
Fecha Fin: 2021-03-31

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 197K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Epilepsy is a neurological disorder characterized by recurrent seizures affecting 65 million people worldwide of which 6 million live in Europe alone with around 30% of patients not responding to currently available treatment. The ATP-gated P2X7 receptor (P2X7R) has recently emerged as a promising target for epilepsy, showing anticonvulsant and disease-modifying properties in animal models. However, to develop P2X7R-based therapeutics the cell types involved in pathological P2X7R activation must be determined, and whether results from rodent models can be replicated in human tissue must be tested. Using human induced pluripotent stem cell-derived neurons and glia and resected brain tissue from epileptic patients, TaPPiNG-EPI proposes to investigate the cell-specific alterations and pathological contribution in the P2X7R pathway and pharmacological targeting of hyperexcitability using P2X7R antagonists. These studies will be complemented by the investigation on the alterations in P2X7R pathway in GFP-P2X7 reporter mice available in the host institution (RCSI). Through international secondments and intersectoral collaborations TaPPiNG-EPI brings together experts in purinergic signalling, industrial partners, epilepsy clinicians as well as leading European academic labs with diverse expertise. The interdisciplinary and intersectoral components of TaPPiNG-EPI combined with international collaborations and secondments in academia, the excellent training record of the supervisor and RCSI and the outstanding resources for learning and development available at RCSI will give me the tools necessary to achieve research independence and my transition to a highly employable future neuroscientist with a focus on epilepsy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores